Lincoln Pharmaceuticals Ltd. reported its June quarter results on Thursday, August 7, which were higher on most parameters on a year-on-year basis.The net profit for the quarter came in at ₹28 crore, up 17% from ₹24 crore in the year-ago period. Revenue grew 5% to ₹154 crore from ₹147 crore a year ago.
Operating performance was also decent, with EBITDA rising 4% year-on-year to ₹24 crore, compared to ₹23 crore last year. Margins came flat at 15%.Lincoln Pharma is targeting revenue of ₹1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets.
This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments.
Shares of Lincoln Pharmaceuticals Ltd. are now trading 8.05% higher on Thursday at ₹573.90. The stock is up 1% in the last one month and down 33% on a year-to-date basis.
First Published: Aug 7, 2025 1:25 PM IS
